Third Generation Thrombolytic Agents in the Guidance of Trials [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2004; 32(8): 564-570

Third Generation Thrombolytic Agents in the Guidance of Trials

Ayşe Saatçi YAŞAR1, Asuman BİÇER1, Hasan TURHAN1, Hatice ŞAŞMAZ1

Third Generation Thrombolytic Agents in the Guidance of Trials Third generation thrombolytic agents were developed to have prolonged half-lives, improved enzymatic efficiency, resistance to plasma protease inhibitors and fibrin binding selectivity. Reteplase, tenecteplase, lanoteplase, monteplase, pamiteplase and staphylokinase are third generation thrombolytic agents. A common feature of these agents is their prolonged half-life in plasma, this makes them suitable for single or repeated bolus injections. Compared with the second generation agents, third generation thrombolytic agents result in a greater angiographic patency rate in patients with acute myocardial infarction. However, mortality rates have been similar. (Türk Kardiyol Dern Arş 2004; 32: 564-570)

Keywords: Coronary artery disease, myocardial infarction, thrombolytic agents

How to cite this article
Ayşe Saatçi YAŞAR, Asuman BİÇER, Hasan TURHAN, Hatice ŞAŞMAZ. Third Generation Thrombolytic Agents in the Guidance of Trials. Turk Kardiyol Dern Ars. 2004; 32(8): 564-570
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale